The CurePSP Genetics Program

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
PSPPSP - Progressive Supranuclear PalsyCorticobasal SyndromeCorticobasal Syndrome(CBS)Corticobasal Degeneration SyndromeCorticobasal DegenerationCorticobasal Degeneration (CBD)Corticobasal Syndrome (CBS)MSAMSA - Multiple System AtrophyMSA-CMultiple System AtrophyMultiple System Atrophy (MSA) with Orthostatic HypotensionMultiple System Atrophy - Cerebellar Subtype (MSA-C)Multiple System Atrophy - Parkinsonian Subtype (MSA-P)Multiple System Atrophy, Cerebellar TypeMultiple System Atrophy, Parkinsonian TypeProgressive Supranuclear PalsyProgressive Supranuclear Palsy(PSP)Progressive Supranuclear Palsy (PSP)
Interventions
OTHER

Whole genome sequencing will be performed at the NIH

All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

CurePSP Foundation

UNKNOWN

collaborator

National Institutes of Health (NIH)

NIH

lead

Massachusetts General Hospital

OTHER